India Rejects Patents For GSK Diabetes Drug, Pfizer Anti-Cholesterol
This article was originally published in PharmAsia News
Executive Summary
India's patent authority turned down protection for GlaxoSmithKline's diabetes and Pfizer's cholesterol drugs, exposing them to generic competition. The Delhi Patent Office said GSK did not make a case that its Avandia (rosiglitazone) was more efficacious than a previous version, freeing generics by Dr. Reddy's Laboratories, Sun Pharma and Torrent Pharma. The office also rejected Pfizer's Caduet, which combines its Norvasc (amlodipine) and Lipitor (atorvastatin). Torrent raised objections about a Caduet patent and the Patent Office agreed. (Click here for more
You may also be interested in...
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.